{"id":"W2146701863","doi":"10.1016/s1470-2045(13)70501-1","title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":270,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Brentuximab vedotin; ABVD; Medicine; Dacarbazine; Internal medicine; Vinblastine; Oncology; Bleomycin; Phases of clinical research; Lymphoma; Surgery; Chemotherapy; CD30; Vincristine; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001508939,0.001438859,0.002440451,0.0005121463,0.0003612293,0.001475962,0.0008498066,0.001085842,0.00213632],"category_scores_gemma":[0.001106786,0.0007188171,0.001453167,0.0005150724,0.001137627,0.001416599,0.0003426358,0.0039743,0.0006595876],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000992362,"about_ca_system_score_gemma":0.0008748848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001076442,"about_ca_topic_score_gemma":0.002424602,"domain_scores_codex":[0.999472,0.0002441313,0.00002264326,0.0000875352,0.0000525668,0.0001212361],"domain_scores_gemma":[0.9991571,0.0002115988,0.0001430953,0.00008141888,0.00003785254,0.000368946],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7893898,0.05256401,0.007913586,0.0009404066,0.002482708,0.0002148362,0.0004117153,0.003374712,0.01597912,0.0003470634,0.002492204,0.1238899],"study_design_scores_gemma":[0.6697789,0.3113033,0.01292945,0.00004999443,0.0007747525,0.0001836293,0.00009987273,0.00131095,0.001321648,0.0002987504,0.001906094,0.00004268993],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952751,0.002287279,0.0003308057,0.0002852929,0.0001272157,0.0004581418,0.0004142864,0.00004798614,0.0007738405],"genre_scores_gemma":[0.9931331,0.002433496,0.0009126168,0.0006930373,0.0001710844,0.0005081284,0.0007959332,0.00002520558,0.00132749],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002440451,"threshold_uncertainty_score":0.007980108,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05715420935216558,"score_gpt":0.3593148764130715,"score_spread":0.3021606670609059,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}